UCB is in San Diego for DIA-Global 2019 this week. Ahead of her presentation, Liz Roberts, our Global Public Policy Lead, shares insights from the industry perspective on clinical trial disclosure and data transparency, and what UCB is doing to keep patients at the center of our work in this space. For more, see Liz speak today, June 25, 2019 at 2:00 p.m. in room 4 (session #260).

From discovery to development to delivery, how we do business has been transformed and redesigned around the patient’s individual experience. At UCB, patients are at the heart of everything we do, inspiring us and driving the ways in which we research, develop, and study differentiated treatments for patients. For 18 years, UCB BioSciences has been in the Research Triangle Park (RTP) in North Carolina and is an integral part of UCB’s mission to bring differentiated medicines to patients.

UCB’s Key Pipeline Molecule Bimekizumab Demonstrated Improved Outcomes for Ankylosing Spondylitis Patients

At UCB, how we do science – from discovery to development to delivery – has been transformed and redesigned around understanding the patient and their individual experience. For specific patient populations new to UCB – like Myasthenia gravis (MG) – this is especially important because no two experiences of this rare, neuromuscular condition are alike. In honor of Myasthenia Gravis Awareness Month, join us as we shine a spotlight to help spread awareness and empower people living with MG.

Every day, UCB researchers come to work driven by a singular purpose – to create value for people living with severe disease. That’s because, across the world, patients depend on the important work of scientific research to find new medical innovations that will help them achieve their goals. From the “breakthrough” moments in discovery, development, and delivery, we are dedicated to finding solutions for the unmet needs of patients.